Your browser is no longer supported. Please, upgrade your browser.
Settings
SEEL Seelos Therapeutics, Inc. daily Stock Chart
SEEL [NASD]
Seelos Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.59 Insider Own7.30% Shs Outstand46.60M Perf Week-1.09%
Market Cap22.86M Forward P/E- EPS next Y-0.44 Insider Trans0.00% Shs Float36.82M Perf Month-43.30%
Income-51.30M PEG- EPS next Q-0.22 Inst Own7.30% Short Float2.09% Perf Quarter-63.80%
Sales0.40M P/S57.14 EPS this Y-123.80% Inst Trans-19.86% Short Ratio0.98 Perf Half Y-46.57%
Book/sh0.00 P/B- EPS next Y31.70% ROA-410.60% Target Price6.00 Perf Year-84.43%
Cash/sh0.22 P/C2.22 EPS next 5Y- ROE- 52W Range0.45 - 3.44 Perf YTD-63.40%
Dividend- P/FCF- EPS past 5Y56.90% ROI- 52W High-86.51% Beta1.11
Dividend %- Quick Ratio1.00 Sales past 5Y-47.30% Gross Margin- 52W Low3.11% ATR0.09
Employees6 Current Ratio1.00 Sales Q/Q- Oper. Margin- RSI (14)30.33 Volatility13.32% 13.90%
OptionableNo Debt/Eq- EPS Q/Q-203.70% Profit Margin- Rel Volume0.59 Prev Close0.49
ShortableYes LT Debt/Eq- EarningsApr 09 BMO Payout- Avg Volume784.53K Price0.46
Recom2.00 SMA20-25.10% SMA50-45.72% SMA200-62.37% Volume312,507 Change-5.40%
Nov-14-19Initiated The Benchmark Company Speculative Buy $4
May-14-19Initiated ROTH Capital Buy
Mar-24-20 08:01AM  Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002) GlobeNewswire
Mar-16-20 04:30PM  Seelos Therapeutics Announces Closing of Public Offering of Common Stock GlobeNewswire -17.30%
Mar-11-20 08:30PM  Seelos Therapeutics Announces Pricing of $4.5 Million Public Offering of Common Stock GlobeNewswire -9.30%
04:15PM  Seelos Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
08:01AM  Seelos Therapeutics Announces European Medicines Agency Guidance to Design an Open-Label Pivotal Study for SLS-005 in Sanfilippo Syndrome GlobeNewswire
Mar-06-20 08:01AM  Seelos Therapeutics Receives Notice of Allowance for Composition of Matter Patent for SLS-007 GlobeNewswire +5.02%
Feb-26-20 08:01AM  Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002) GlobeNewswire -7.59%
Feb-19-20 08:02AM  Seelos Therapeutics to Participate in Two Upcoming Investor Conferences in March GlobeNewswire -6.14%
Feb-17-20 08:57AM  Raj Mehra Is The Founder of Seelos Therapeutics, Inc. (NASDAQ:SEEL) And They Just Spent US$100k On Shares Simply Wall St.
Feb-13-20 04:30PM  Seelos Therapeutics Announces Closing of Public Offering of Common Stock GlobeNewswire
Feb-10-20 08:00PM  Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock GlobeNewswire
Jan-28-20 01:58PM  Did You Manage To Avoid Seelos Therapeutics's (NASDAQ:SEEL) Devastating 73% Share Price Drop? Simply Wall St. +5.32%
08:02AM  Seelos Therapeutics Announces Update to Parkinsons Disease Program SLS-007 GlobeNewswire
Jan-22-20 07:30AM  Seelos Therapeutics Announces Updates to SLS-005 (trehalose) Programs for Europe and U.S. GlobeNewswire -10.93%
Jan-10-20 08:30AM  Sorrento shares rise on private equity proposal MarketWatch
07:31AM  Seelos Therapeutics Announces Interim Data from Phase I Study of Intranasal Racemic Ketamine (SLS-002) GlobeNewswire
Jan-06-20 08:02AM  Seelos Therapeutics Schedules Type C Meeting with FDA to Discuss Intranasal Racemic Ketamine Program (SLS-002) GlobeNewswire +6.77%
Dec-16-19 07:00AM  Sorrento Announces Dr. Robin Smith as New Member of the Board of Directors GlobeNewswire +7.14%
Dec-13-19 08:30AM  Seelos Therapeutics to Participate in 33rd Annual National MPS Society Family Conference GlobeNewswire
Dec-04-19 08:00AM  Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005) GlobeNewswire +8.98%
Nov-30-19 10:18AM  Hedge Funds Have Never Been More Bullish On Seelos Therapeutics, Inc. (SEEL) Insider Monkey
Nov-27-19 11:00AM  Seelos Therapeutics Announces Dosing of Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002) GlobeNewswire
Nov-20-19 09:00AM  Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002) GlobeNewswire
Nov-18-19 08:00AM  Seelos Therapeutics Receives FDA Fast Track Designation for Intranasal Racemic Ketamine (SLS-002) GlobeNewswire
Nov-08-19 07:00AM  Seelos Therapeutics Reports Q3 2019 Pipeline Update GlobeNewswire
Nov-01-19 10:00AM  Seelos Therapeutics to Participate in Upcoming Investor Conferences in December GlobeNewswire
Oct-21-19 09:00AM  Seelos Therapeutics Announces Amendment of SLS-002 Agreement GlobeNewswire
Oct-18-19 09:00AM  Seelos Therapeutics to Participate in Upcoming Investor Conference in November GlobeNewswire
Oct-15-19 09:00AM  Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant GlobeNewswire
Sep-04-19 09:00AM  Seelos Therapeutics to Participate in Upcoming Investor Conference in September GlobeNewswire
Aug-23-19 09:00AM  Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct Offering GlobeNewswire -15.73%
Aug-22-19 02:24PM  What Kind Of Investor Owns Most Of Seelos Therapeutics, Inc. (NASDAQ:SEEL)? Simply Wall St. +7.88%
09:00AM  Seelos Therapeutics Announces FDA Acceptance of IND Application for SLS-005 for Mucopolysaccharidosis Type III (Sanfilippo Syndrome) GlobeNewswire
Aug-14-19 06:00PM  Seelos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-06-19 09:00AM  Seelos Therapeutics to Ring Opening Bell at Nasdaq on August 12th GlobeNewswire
Aug-01-19 09:00AM  Seelos Therapeutics Reports Q2 2019 Pipeline Update GlobeNewswire -9.71%
Jul-17-19 09:00AM  Seelos Therapeutics Announces Investigational New Drug Application Submission for SLS-005 GlobeNewswire
Jul-15-19 11:00AM  Seelos Therapeutics Announces Receipt of a Grant for Funding of SLS-005 Program GlobeNewswire
Jul-02-19 11:00AM  Seelos Therapeutics Receives Notice of Allowance for a US Patent for SLS-005 in New Indication of Friedreich Ataxia GlobeNewswire
Jul-01-19 09:00AM  Seelos Therapeutics Added to Russell Microcap® Index GlobeNewswire
Jun-28-19 11:38AM  A Look At Benzinga Pro's Most-Searched Tickers For June 28, 2019 Benzinga -5.60%
Jun-27-19 07:00AM  Seelos Therapeutics Announces Acquisition of an Exclusive Worldwide License of Gene Therapy Program to Address Parkinsons Disease from Duke University GlobeNewswire
Jun-06-19 07:00AM  Seelos Therapeutics Provides Update on Pipeline Developments and Corporate Highlights GlobeNewswire
May-21-19 08:30AM  Seelos Therapeutics Reports Q1 2019 Pipeline Update GlobeNewswire
Apr-16-19 08:00AM  Seelos Therapeutics to Participate at the Jefferies 2019 Global Healthcare Conference in NYC GlobeNewswire
Apr-02-19 01:15PM  Two Months into a Reverse Merger, Where Does Seelos Therapeutics Stand Now? ACCESSWIRE
Mar-29-19 02:43PM  Why Seelos Therapeutics Shares Are Surging Out Of The Gate Benzinga +17.48%
Mar-28-19 05:00PM  Seelos Therapeutics Provides Update on Pipeline Developments and Corporate Highlights GlobeNewswire
Mar-27-19 09:25AM  Four Healthcare Stocks Picking Up Speed on Wednesday ACCESSWIRE
Mar-13-19 07:30AM  A Near Term FDA Clearance That Could Be The Beginning Of The Brain-Computer Revolution? ACCESSWIRE -14.29%
Mar-08-19 09:37AM  Shares of Seelos Therapeutics up 80% Friday morning MarketWatch +11.51%
09:35AM  Four Healthcare Stocks Looking To Close Out a Strong Week on Friday ACCESSWIRE
Mar-07-19 08:00AM  Seelos Therapeutics Announces Acquisition of an Exclusive License to Intellectual Property from The UC Regents to Potential Disease-Modifying Parkinson's Disease Therapy Created at UCLA GlobeNewswire +96.13%
Mar-06-19 02:45PM  Four Tech Stocks To Watch on Wednesday ACCESSWIRE
08:00AM  Seelos Therapeutics to Webcast Presentation at the 39th Annual Cowen Health Care Conference and Participate in the 31st Annual ROTH Conference GlobeNewswire
Mar-01-19 09:00AM  Seelos Therapeutics to Present at the 39th Annual Cowen Health Care Conference GlobeNewswire -13.51%
Feb-19-19 08:00AM  Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma GlobeNewswire -5.99%
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with Parkinson's disease or Lewy Body Dementia; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and orphan indications; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. The company was founded in 2016 and is headquartered in New York, New York.